Increased suicide risk in patients with hidradenitis suppurativa - Thorlacis L, Cohen AD, Gislason GH, Jemec GBE, Egeberg A.
Patients with skin disorders are considered at a higher risk of depression and anxiety than the background population. Patients with hidradenitis suppurativa (HS) may be particularly affected. We explored the association between HS and depression, anxiety,... (Source: SafetyLit)
Source: SafetyLit - September 29, 2017 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Biofilm-based Treatment for Chronic Hidradenitis Suppurativa Biofilm-based Treatment for Chronic Hidradenitis Suppurativa
Mounting evidence that biofilms are involved in hidradenitis suppurativa suggests that a biofilm-based treatment strategy, such as used in other chronic wound infections, may be effective.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 15, 2017 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

New treatment options for common debilitating skin disease Hidradenitis suppurativa
(Trinity College Dublin) The research team behind the study pinpointed 'Th17' cells as mediating the disease (HS). A number of existing treatments target the same cellular pathway and may also be effective in treating HS. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 19, 2017 Category: Biology Source Type: news

Glaswegian woman with lumps in groin thought it was STI
Esme Munro, 35, from Glasgow, mistook the huge, puss-filled lumps for an STI until she was diagnosed  with hidradenitis suppurativa, caused by blocked sweat glands. (Source: the Mail online | Health)
Source: the Mail online | Health - June 13, 2017 Category: Consumer Health News Source Type: news

GRAPHIC IMAGES: Incurable skin condition causes painful abscesses - do you have symptoms?
HIDRADENITIS suppurativa is a painful, long-term skin condition that causes recurring boils and abscesses, usually around the armpits, groin, on the buttocks and under the breasts. (Source: Daily Express - Health)
Source: Daily Express - Health - June 9, 2017 Category: Consumer Health News Source Type: news

Hematological Parameters in Staging Hidradenitis Suppurativa Hematological Parameters in Staging Hidradenitis Suppurativa
What role could hematological markers potentially play in the evaluation of hidradenitis suppurativa?Wounds (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - June 5, 2017 Category: Pathology Tags: Dermatology Journal Article Source Type: news

Wound Healing and Hidradenitis Suppurativa
(MedPage Today) -- Draining lesions call for specialized attention (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 2, 2017 Category: Primary Care Source Type: news

Hidradenitis suppurativa, intimate partner violence, and sexual assault - Sisic M, Tan J, Lafreniere KD.
BACKGROUND: Sexual assault and intimate partner violence have never been examined in individuals with hidradenitis suppurativa. The research is important, because prior studies show higher incidences of intimate partner violence and sexual assault in indiv... (Source: SafetyLit)
Source: SafetyLit - May 12, 2017 Category: International Medicine & Public Health Tags: Jurisprudence, Laws, Legislation, Policies, Rules Source Type: news

European Commission Approves AMGEVITA ™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
First Biosimilar Adalimumab Approved in the European Union THOUSAND OAKS, Calif., March 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for AMGEVITA™ (biosimilar adalimumab1) in all available indications. AMGEVITA is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic plaque psoriasis; moderate-to-severe hi...
Source: Amgen News Release - March 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

AbbVie's HUMIRA(R) (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
NORTH CHICAGO, Ill., Nov. 14, 2016 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has gr... Biopharmaceuticals, Dermatology, Regulatory AbbVie, HUMIRA, adalimumab, hidradenitis suppurativa (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 14, 2016 Category: Pharmaceuticals Source Type: news

Adalimumab for the Treatment of Hidradenitis Suppurativa Adalimumab for the Treatment of Hidradenitis Suppurativa
Hidradenitis suppurativa is a severe and chronic auto-inflammatory disease, with few therapeutic options, but recent Phase III clinical trials on the efficacy of adalimumab show promise.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 26, 2016 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Humira Partially Effective Against Hidradenitis Suppurativa Humira Partially Effective Against Hidradenitis Suppurativa
The anti-inflammatory drug adalimumab can provide significant relief for about a quarter of people who suffer from a moderate-to-severe case of the chronic skin condition hidradenitis suppurativa, according to two 36-week trials.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 4, 2016 Category: Consumer Health News Tags: Dermatology News Source Type: news

Clinical trial results support adalimumab treatment for painful skin condition
The results of two phase 3 clinical trials that led to FDA approval of adalimumab for treatment of the chronic inflammatory skin disease hidradenitis suppurtiva are now being published. An inhibitor of the inflammatory protein tumor necrosis factor, adalimumab is the first such medication approved to treat the painful skin disorder. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 4, 2016 Category: Science Source Type: news

Studies highlight diagnostic and treatment challenges in hidradenitis suppurativa
SCOTTSDALE, ARIZ. – Patients with hidradenitis suppurativa (HS) may be misdiagnosed when they see providers who are not dermatologists – as is usually the case during the initial years of their disease, according to a large analysis of medical claims data. The findings highlight the need for... (Source: Skin and Allergy News)
Source: Skin and Allergy News - August 3, 2016 Category: Dermatology Source Type: news